number of access : ?
number of downloads : ?
ID 115032
Title Alternative
Brodalumab in patients with GPP and PsE
Author
Yamasaki, K. Tohoku University
Nakagawa, H. The Jikei University
Ootaki, K. Kyowa Hakko Kirin
Content Type
Journal Article
Description
Background
A T‐helper (Th) cell subset Th17 preferentially produces interleukin (IL)‐17 and plays a pivotal role in the pathogenesis of psoriasis. However, the pathological roles of IL‐17 cascades in generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE) have not been well established.
Objectives
To evaluate the efficacy and safety of brodalumab, a human immunoglobulin G2 monoclonal antibody against human IL ‐17‐receptor A (IL‐17RA), in Japanese patients with GPP and PsE.
Methods
This was an open‐label, multicentre, long‐term phase III study in Japanese patients with rare and severe types of psoriasis. Patients received brodalumab 140 mg at day 1 and weeks 1 and 2, and then every 2 weeks until week 52. The primary endpoint was the Clinical Global Impression of Improvement (CGI). Safety evaluations included treatment‐emergent adverse events (AEs) and changes in laboratory parameters.
Results
A total of 12 patients with GPP and 18 with PsE were enrolled. Ten patients with GPP and 16 with PsE completed the study. At week 52 (last observation carried forward), CGI remission or improvement was achieved in 11 patients with GPP and 18 with PsE. The most commonly reported AE was nasopharyngitis (33·3%). Five serious AE s occurred during the study. However, none was considered treatment‐related.
Conclusions
Brodalumab significantly improved the symptoms of patients with GPP and PsE throughout the 52 weeks, and demonstrated favourable safety profiles without any new safety signals. Inhibition of IL‐17RA‐mediated signalling by brodalumab is expected to be a promising new treatment option for patients with GPP and PsE.
Journal Title
British Journal of Dermatology
ISSN
13652133
Publisher
British Association of Dermatologists|Wiley & Sons
Volume
176
Issue
3
Start Page
741
End Page
751
Published Date
2016-04-23
Rights
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License(https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences